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Relationship between tamoxifen-induced transforming growth factor Pi3
expression, cytostasis and apoptosis in human breast cancer cells
RR Perry, Y Kang and BR Greaves
Division ofSurgical Oncology, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA.
Summary Previously we have shown that tamoxifen (TAM) induces morphological and biochemical changes
typical of apoptosis in oestrogen receptor (ER)-positive MCF-7 or ER-negative MDA-231 human breast
cancer cells. In this study the effects of TAM on expression of transforming growth factor PI (TGF-P1) were
correlated with the effects on cell cycle kinetics and apoptosis. TAM had similar biphasic effects on both cell
lines. Short-term (<6 h) TAM incubation resulted in a slight decrease in TGF-l31 protein despite an increase
in TGF-P1 mRNA and was associated with an increase in cells in S-phase. No apoptotic effects were noted.
Longer ( > 12 h) TAM incubation induced TGF-PI protein (about 3-fold) and mRNA expression (about
2-fold) in both cell lines, and was associated with GI/Go blockade and induction of apoptosis. The accumula-
tion ofTAM-induced TGF-PI mRNA was increased by cycloheximide, but was not affected by 17 P-oestradiol.
Long-term incubation with TAM had no significant effect on TGF-PI gene copy number. TAM-induced
internucleosomal DNA cleavage was inhibited in both cell lines by the addition of an anti-TGF-P1 antibody.
TAM has dose- and time-dependent effects on TGF-PI expression associated with changes in cell cycle kinetics.
These effects are independent of ER status and may be the result of a direct regulatory effect of TAM on
TGF-P1 transcription. It also appears that induction of TGF-PI plays an important role in TAM-induced
apoptosis in breast cancer cells.
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The mechanism of action of the anti-oestrogen tamoxifen
(TAM) is unclear, but it is apparent that TAM has both
oestrogen receptor (ER) and non-ER mediated cytostatic
activity. Previous observations by our group (Kang and
Perry, 1993) and others (Reddel et al., 1984; Dickson et al.,
1990) have shown that the time- and dose-dependent growth
inhibitory effects of TAM have a biphasic character. TAM
may have important biological effects via novel pathways,
such as through modulation of transforming growth factor P
(TGF-P1) activity (Butta et al., 1992). TGF-P1 has either
growth inhibitory or growth stimulatory properties, depen-
ding on the concentration and cell type (Roberts et al., 1985).
TGF-PI appears to be an important negative regulator of
breast cancer cell growth. ER( + ) MCF-7 breast cancer cells
(Roberts et al., 1985; Knabbe et al., 1987), and four ER( -)
breast cancer cell lines including MDA-231 (Arteaga et al.,
1988) secrete and are inhibited by TGF-pl.
It also appears that TGF-P, may be a mediator of TAM-
induced cytostasis (Manni et al., 1991). Anti-oestrogens
induce TGF-P3 activity in ER( +) MCF-7 cells in vitro
(Knabbe et al., 1987), in ER( -) human fetal fibroblast in
vitro (Colletta et al., 1990), and in both ER( + ) and ER( -)
human breast cancer in vivo (Butta et al., 1992). However,
the induction of TGF-PI is not an absolute requirement for
TAM-induced cytostasis, as demonstrated by other models
including long-term passage MCF-7 cells (Zugmaier and Lip-
pman, 1990) and the ER( +) T47-D breast cancer cell line
(Murphy and Dotzlaw, 1989). Since TGF-PI is rapidly deg-
raded, with the preform having a half-life of 2 h and the
active form only 2 min, active synthesis is required for this
protein to be expressed (Wakefield et al., 1987).
Recent work in our laboratory has shown that TAM can
induce growth stimulation at low dose or growth inhibition
and apoptosis at higher doses in either ER( + ) MCF-7 or
ER( -) MDA-231 human breast cancer cells (Table I; Perry
et al., 1995). TAM induced characteristic morphological
changes associated with apoptosis, including condensation of
chromatin around the nuclear periphery, typical biochemical
changes such as internucleosomal DNA fragmentation and
the process required protein synthesis. Other investigators
have shown that 4-hydroxytamoxifen (Bardon et al., 1987) or
toremifene (Warni et al., 1993) can also induce apoptosis in
MCF-7 cells. The mechanisms whereby TAM induces apop-
tosis remain unknown. However, since TAM induces secre-
tion ofTGF-pl, TGF-P1 may be a mediator of TAM-induced
apoptosis. TGF-P3 induces apoptosis in several model
systems including uterine epithelial cells (Rotello et al., 1991),
and liver cells in vitro and in vivo (Oberhamer et al., 1992;
Bursch et al., 1993). Increased TGF-P3 expression and apop-
tosis are noted in ER-dependent tumours following oestrogen
ablation (Kyprianou et al., 1990). TGF-PI has been detected
early in mammary gland involution (Strange et al., 1992).
But there is no direct evidence showing a relationship
between TAM-induced TGF-P1 expression and TAM-induced
apoptosis in ER( + ) and ER( -) human breast cancer cell
lines.
In the present study we determined the effects of TAM on
TGF-P1 expression, cell cycle kinetics and DNA cleavage in
MCF-7 and MDA-231 cells. We found that TAM had
similar biphasic effects on TGF-PI expression and cell cycle
kinetics in both cell lines. The TAM-induced increase in
TGF-P1 expression strongly correlated with DNA cleavage
characteristic of apoptosis, and this DNA cleavage was
inhibited by addition of an anti-TGF-P, antibody. The data
demonstrate that tamoxifen-induced expression of TGF-P1 is
independent of ER status and appears to be directly linked to
the observed GI/Go arrest, cytostasis and apoptosis.
Materials and methods
Cell lines
The MCF-7 cell line was originally obtained from the
Michigan Cancer Foundation; the MDA-231 cell line was
obtained from American Type Culture Collection (Rockville,
MD, USA). Cells were maintained in a-minimal essential
medium (a-MEM) supplemented with 5% fetal calf serum,
glutamine, penicillin and streptomycin. The cells were
incubated at 37°C in a 95% air/5% carbon dioxide environ-
ment. Forty-eight hours before each experiment the cells were
transferred to phenol-red-free media with charcoal dextran
stripped-fetal calf serum to remove exogenous oestrogens
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Table 1 Time dependence of 10tLM TAM-induced DNA cleavage and cytostasisa
MCF-7 MDA-231
Time (h) DNA cleavage (%) Cell growth (%) DNA cleavage (%) Cell growth
0 4.8 0.7b 100 4.5 + 0.5 100
6 5.1±0.7 123±6 5.5±0.8 109±8
12 8.6 1.1 63±6 4.8±0.9 81 4
24 21.6 1.6 44±7 18.6 1.8 64±9
48 36.9±2.2 4±3 30.6±2.0 7±2
aAdapted from Perry et al. (1995). bMean ± s.e.
(Reddel, 1984). No significant spontaneous apoptosis was
noted when cells were incubated for up to 7 days in the
oestrogen-free medium.
Drugs
Tamoxifen (trans 1-(4-p-dimethylaminoethoxyphenyl)-1, 2-di-
phenylbut-1-ene; TAM) was kindly provided by Zeneca Phar-
maceuticals (Wilmington, DE, USA). A stock solution was
prepared in 2% ethanol and stored at -20°C. All of the
chemicals used were of reagent grade and were obtained
commercially.
Measurement ofcell cycle kinetics
Single cell preparations obtained from control cultures and
cultures treated with 10 ,UM TAM for various periods of time
were fixed in ice-cold methanol for 15 min. This dose of
TAM was chosen based on our previous experiments which
demonstrated dose- and time-dependent growth inhibition
and apoptosis in MCF-7 and MDA-231 cells (Perry et al.,
1995). The cells were -removed from the fixative by cent-
rifugation at 900g for 5 min and stained for DNA flow
cytometry with 50 Lg ml-' propidium iodide. Thirty minutes
before analysis, RNase (ribonuclease type A, Sigma, St
Louis, MO, USA) was added directly to the stained cell
preparations to yield a final concentration of 1.0mgml-1,
and samples were filtered through 40 p nominal pore size
nylon gauze. Analysis was performed using an Epics V elect-
ronically programmable individual cell sorter (Coulter Elect-
ronics, Hialeah, FL, USA) equipped with a MDADS graphic
display (Coulter), with excitation at 488 nm provided by an
argon ion laser operating at 200 mW and fluorescence
detected at greater than 550 nm. Single parameter DNA
histograms were collected for 10000 viable cells, and the cell
cycle kinetic parameters were calculated from the histograms
using the manufacturer's software (Coulter).
Western analysis ofTGF-P, expression
Breast cancer cells were treated with 10JAM TAM for up to
48 h, washed twice with cold phosphate-buffered saline (PBS)
and sonicated for 30 s at 0-4°C. Cytosolic protein (50ytg per
lane) was resolved using 12.5% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) followed by
electrophoretic transfer to polyvinylidene difluoride mem-
branes according to the manufacturer's directions (BioRad,
Richmond, CA, USA). Western immunoblotting was per-
formed using rabbit anti-human TGF-P1, polyclonal antibody
(Oncogene Science, Uniondale, NY, USA). After soaking in
TTBS (100 mM Tris-HCI, pH 7.5, 0.9% sodium chloride, and
0.1% Tween-20), the membranes were incubated with anti-
TGF-3, antibody (1:500) for 6 h at room temperature in
TTBS (containing 5% goat serum). The filters were then
washed three times with TTBS. Biotinylated goat anti-rabbit
IgG was used as the secondary antibody (Vector Labor-
atories, Burlingame, CA, USA) and colour developed using a
commercially obtained avidin-biotin-peroxidase staining kit
(Vector).
Hybridisation probes
TGF-P, cDNA was originally from Dr R Dernyck (Genen-
tech, San Francisco, CA, USA). Glyceraldehyde phosphate
dehydrogenase (GAPDH) cDNA was obtained from Amer-
ican Type Culture Collection. The above DNAs were sub-
cloned in SP6 vectors (Promega Biotec, Madison, WI, USA)
and used as templates for synthesis of high-specific activity
(I09 c.p.m. ig-') 32P-labelled cDNA probes.
Isolation ofRNA and Northern analysis
Total RNA from breast cancer cells treated with 10JAM TAM
for up to 48 h was isolated by the guanidinium isothio-
cyanate method (Maniatis et al., 1982). Poly (A+ )-RNA
was purified using an oligo(dt + )-cellulose column ( x 2). An
aliquot of 5fig of each mRNA preparation was size frac-
tionated using a 1% formaldehyde-agarose gel. The RNA
gel was stained with ethidium bromide before transfer to a
nitrocellulose membrane to monitor the integrity of 18 S and
28 S rRNA bands. Filters were prehybridised in 1 M sodium
chloride, 10% dextran sulphate, 50% formamide and 0.1%
SDS at 42°C for 12 h and then hybridised in 5 x standard
saline citrate (SSC, 1.5M sodium chloride, 0.15 M sodium
citrate), 1 x Denhardt's solution, 0.1 mg ml-' salmon sperm
DNA, 10% dextran sulphate, 45% formamide and 0.05%
SDS with 106 c.p.m. ml-' 32P-labelled TGF-P, cDNA or
GADPH cDNA (as the control) at 42°C for 10h. Filters
were then treated with four 5 min washes in 2 x SSC, 0.1%
SDS at room temperature and then three 15 min washes in
0.2 x SSC, 0.1% SDS at 60°C. Autoradiography was then
performed at - 70°C for 72 h. Relative abundance ofTGF-P,
transcripts was assessed by densitometry, normalised to the
density of the GADPH transcripts.
Other experiments were performed to examine the effects
of certain inhibitors on TAM-induced TGF-P, mRNA exp-
ression. Cells were treated for 24 h with 10JiM TAM alone,
10 JAM TAM plus 10JAM 17p-oestradiol, or with 10 JAM plus
0.35 JAM cycloheximide. This concentration of cycloheximide
inhibited protein synthesis by greater than 90% and when
given alone did not induce TGF-,B, expression or induce
apoptosis (data not shown).
Isolation ofDNA and Southern analysis
To measure TGF-P, gene copy number, Southern analysis
was performed as described by others (Ueda et al., 1987).
Genomic DNA was extracted from breast cancer cells treated
with 10JAM TAM for up to 120 h and then digested overnight
with a 2-fold excess of the EcoRI restriction endonuclease.
An aliquot of 10yg of each sample was then resolved by
electrophoresis on a 0.8% agarose gel and transferred to
Nytran membranes (Schleicher & Schuell, Keene, NH, USA)
using 10 x SSC. The blotted DNAs were then hybridised
under high-stringency conditions (68°C) with 106 c.p.m. ml-'
of 32P-labelled TGF-1, cDNA. Filters were treated with four
5 min washes in 1 x SSC, 0.1% SDS at room temperature,
followed by three 15 min washes in 0.1 x SSC, 0.1% SDS at
55°C. Autoradiography was performed using Kodak X-
OMAT AR film with Cronex intensifying screens at - 75°C
for 72 h. Equal loading of DNA was confirmed by ethidium
bromide staining of the gels and by rehybridisation of the
filters with a GADPH probe.
Analysis ofDNAfragmentation
Approximately 4 x 106 breast cancer cells were seeded into
75cm2 flasks (Falcon, Becton Dickson). After 24 h the cellsTamoxifen, TGF-P1, cell cycle and apoptosis
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Table II Effects of TAM on cell cycle kinetics
G1/Go (%) S (%) G2/M(%)
Time (h) MCF-7 MDA-231 MCF-7 MDA-231 MCF-7 MDA-231
0 45 3a 51 2 31 5 29 5 24 4 20 5
6 44±4 42±3 36±5 38±6 20±3 20±3
12 53±3 50±3 28±4 29±6 19±3 21 4
24 66±4 58±4 24±6 24±2 10±5 18±3
48 73±4 70±5 20±3 18±5 7±3 12±2
aMean ± s.e.
0 6 12 24 48
Figure 1 DNA histograms of MCF-7 and MDA-231 cells treated with 10 LM TAM for various periods of time. The results shown
are typical of the five assays performed.
were treated at 37°C for 24 h with 10 gM TAM alone or with
addition of anti-TGF-,B antibody (Oncogene Science). Cel-
lular DNA from each treatment group was isolated from
5 x 106 cells. The cells were washed in PBS and the cell pellet
was resuspended in 1.0 ml of0.15 M sodium chloride, 0.015 M
sodium citrate, 10 mM EDTA (pH 7.0), containing 1% (w/v)
sodium lauryl sarkosinate and 0.5 mgmll proteinase K.
Proteolytic digestion was allowed to proceed at 50°C for 2 h.
The DNA was precipitated with two volumes of absolute
ethanol, resuspended in 10 mM Tris-HCI, 1 mM EDTA buffer
(pH 8.0), heated to 70°C and loaded onto a 1.6% agarose
gel. Pulse-field electrophoresis was carried out in 40 mM Tris-
acetate, 1 mM EDTA (pH 8.0), until the marker dye had
migrated 4-5 cm. The gels were stained with ethidium
bromide and DNA was visualized under UV light.
Results
Effects of TAM on cell cycle kinetics
MCF-7 or MDA-231 cells were treated with 1OYLM TAM for
various periods of time and subjected to flow cytometric
analysis. The results revealed that TAM treatment of 6 h
resulted in an increase in cells entering S-phase (Table II).
TAM treatment for > 24 h induced a time-dependent block-
ade in GI/Go (Figure I, Table II). There was no significant
difference between the cell cycle kinetic changes induced in
the ER(+) MCF-7 and the ER(-) MDA-231 cell lines.
Breast cancer cells were also treated with 1-50 t5M TAM for
24 h. TAM also induced a dose-dependent blockade of
MCF-7 and MDA-231 cells in GI/Go, and the dose-
dependence and degree of the blockade were similar in both
cell lines (data not shown).
Effects of TAM on TGF-P, protein determined by Western blot
Cytosolic protein was isolated from breast cancer cells
treated with 10tM TAM for up to 48 h, and the protein
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Figure 2 Effects of TAM on TGF-,B, protein in MCF-7 and
MDA-231 cells. (a) Cells were treated with 10 gM TAM for up to
48 h and subjected to Western blotting. (b) TGF-P, bands from
four separate experiments quantified using laser densitometry,
mean ± s.e. (0, MCF-7; 0, MDA-231).
subjected to electrophoretic separation and immunoblotting.
The results revealed that TAM had a time-dependent effect
on TGF-P1 protein (Figure 2). There was no significant
difference in the degree or time course of the TGF-P, induc-
tion between MCF-7 and MDA-231 cells. TAM treatment
Time (h)
MCF-7
MDA-231
I
son
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for 6 h resulted in a slight but non-significant decrease of
TGF-13I protein, accompanied by a slight increase in cell
growth (Table I) and an increase in the number of cells
entering S-phase (Table II). TAM treatment for 12-48 h
resulted in a progressive increase of TGF-P1 protein. This
increase in TGF-P3 protein preceded the GI/Go block (Figure
1) and correlated with DNA cleavage (Figure 3). TAM also
caused a dose-dependent induction of TGF-P1 protein, which
was similar in both cell lines (data not shown).
Effects of TAM on TGF-P, mRNA expression determined by
Northern blot
Total cellular RNA from breast cancer cells treated with
1OgiM TAM for up to 48 h was isolated and subjected to
Northern blot hybridisation (Figure 4). There was no
significant difference in relative abundance of TGF-P1 trans-
cripts between MCF-7 and MDA-231 cells under control
conditions. TAM treatment increased mRNA expression in
both cell lines, but the induction was faster in ER( + ) MCF-
7 cells, with maximal levels of TGF-P3 mRNA reached by
6 h. Maximal levels of TGF-,B, mRNA in ER( -) MDA-231
cells were reached by 12 h.
A variety of inhibition experiments were then performed to
determine the effects on TAM-induced TGF-P1 mRNA ex-
pression. Cells were incubated for 24 h with 1OpM TAM
alone or with TAM and various inhibitors. Again, TAM
significantly increased TGF-P1 mRNA expression in MCF-7
(0) and MDA-231 (U) cells compared with saline-treated
control cells (Figure 5). The addition of 1OgiM 17l-oestradiol
failed to block TAM induction of TGF-PI mRNA in either
cell line, suggesting that TAM induction of TGF-P3 is
independent of ER. Inhibition of protein synthesis by cyc-
loheximide significantly increased the accumulation of TAM-
induced TGF-13I mRNA in both cell lines, suggesting that
TAM may also induce protein(s) which negatively regulate
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Figure 4 Effects of TAM on TGF-P1 mRNA expression. (a)
MCF-7 cells and MDA-231 cells were treated with 10 M TAM
for up to 48 h and subjected to Northern blotting. (b) Relative
TGF-P, mRNA levels of four separate experiments quantified by
laser densitometry and normalised to the GAPDH transcript,
mean±s.e. (0, MCF-7; 0, MDA-231).
a
MCF-7 MDA-231
e1 1% e5 A -1 1% MCF-7
I
I
2.5 kb -
TGF-,1
1.4 kb -
GAPDH
10 20
DNA cleavage (%)
30 40
MDA-231
10 20
DNA cleavage (%)
30
Figure 3 Correlation between TAM-induced TGF-P, protein
expression and internucleosomal DNA cleavage. MCF-7 and
MDA-231 cells were treated with 1OgM for up to 48 h. TGF-P,
protein was determined by Western blotting as shown in Figure
2. DNA cleavage data is from Perry et al. (1995). Results shown
are mean ± s.e. of four separate experiments.
b
c 250
-
200
.0
co 150
-
Z 100 .
E
50 .
Cont TAM TAM+E2 TAM+CX
(1) (2) (3) (4)
I Figure 5 Effects of 17P-oestradiol and cycloheximide on TAM
induction of TGF-P1 mRNA expression. MCF-7 and MDA-231
cells were treated with TAM and various inhibitors for 24 h. (a)
A representative Northern blot. Cells were incubated for 24h
with saline (lane 1), 10 jM TAM (lane 2), 10 gM TAM + 10 jAM
17P-oestradiol (lane 3) or 1Og1M TAM+ 0.35 jAM cycloheximide
(lane 4). (b) Relative TGF-P, mRNA levels of four separate
experiments quantified by laser densitometry and normalised to
the GADPH transcript, mean ± s.e. (0, MCF-7; MDA-231).
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f%TGF-P1 expression. Others have shown that cycloheximide in
certain models can increase death-associated mRNAs (Owens
et al., 1991). Cycloheximide alone had no effect on TGF-P3
expression (data not shown).
Effects of TAM on TGF-f3, gene copy number
Because the TAM-induced increase in TGF-P3 expression
occurred over a relatively short time scale, it seemed unlikely
that this increase was due to gene amplification. Nonetheless,
TAM can rapidly effect cellular genes (Lau et al., 1991). We
therefore determined if the effects of TAM on TGF-1B, exp-
ression were due to amplification of the TGF-P1 gene.
Genomic DNA was isolated from breast cancer cells treated
with 10 JIM TAM for up to 48 h, and subjected to Southern
blotting. There was no significant difference in TGF-PI gene
copy number in MCF-7 and MDA-231 cells under control
conditions, and TAM had no significant effect on TGF-,1
DNA gene copy number (data not shown). Thus, the TAM-
induced increase in TGF-P1 expression was not due to gene
amplification. TAM treatment for up to 120 h also did not
increase TGF-P1 gene copy number (data not shown).
Effects ofAnti-TGF-P, antibody on TAM-induced DNA
cleavage
TAM induction of TGF-P3 highly correlated with inter-
nucleosomal DNA cleavage (Figure 3). Therefore, the ability
of TAM to induce internucleosomal DNA cleavage was
determined in the presence or absence of anti-TGF-P1
antibody. TAM alone induced DNA cleavage typical of
apoptosis in MCF-7 and MDA-231 cells (Figure 6). The
addition of an irrelevant isotype control antibody failed to
inhibit TAM-induced DNA cleavage. However, the addition
of anti-TGF-Pf antibody inhibited TAM-induced DNA
cleavage in both cell lines.
Discussion
TAM has time- and dose-dependent effects on TGF-,13 ex-
pression and cell cycle kinetics in MCF-7 and MDA-231
cells. The effects ofTAM on cell cycle kinetics have been well
described by our laboratory (Kang and Perry, 1993) and
others (Osborne et al., 1983). TAM blocks both MCF-7 and
MDA-231 cells in GI/Go, indicating that the effect of TAM
on cell cycle kinetics is independent of ER. The results of this
study show a good correlation between TAM induction of
TGF-P1 and cell cycle blockade in GI/Go, which may at least
partially explain the cytostatic effects of TAM. The time
course of TAM-induced alterations in TGF-P3 expression and
cell cycle kinetics was similar to the time course of TAM-
induced apoptosis seen in our previous study (Perry et al.,
1995). TAM induction of TGF-P1 correlated strongly with
internucleosomal DNA cleavage. Also, addition ofanti-TGF-
PI antibody completely inhibited TAM-induced DNA clea-
vage. These data suggest that TGF-P1 is an important
mediator of TAM-induced apoptosis.
The effects of TAM on TGF-P1 expression are complex
and independent of ER status. TAM treatment for 6 h
caused a slight decrease in TGF-P1 expression which was
accompanied by an increase in cell growth and the percen-
tage of cells in S-phase. This decrease in TGF-P1 expression
was probably caused at the translational level since TGF-13I
mRNA levels were increased during this time interval. TAM
treatment of > 12 h caused an increase in TGF-13I expression
which correlated highly with and preceded the observed G1/
Go arrest. This induction of TGF-P, was accompanied by a
parallel increase in TGF-P, mRNA and occurred in the
absence of TGF-P, gene amplification, suggesting TAM has
regulatory effects at the transcriptional or post-trans-
criptional levels.
TAM induction of TGF-1,B precedes apoptosis, since
TGF-P, mRNA was induced by 6-12 h and DNA cleavage
and apoptosis in our previous study was not observed until
Tamoxifen,TGF-cle, cell cycle and apoptosis
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Figure 6 Effects of anti-TGF-P, antibody on TAM-induced
DNA cleavage. MCF-7 and MDA-231 cells were treated with
10 JM TAM alone or along with antibody for 24h. DNA was
isolated and then subjected to agarose gel electrophoresis to
measure DNA cleavage. Cells were treated with saline (lanes 1
and 6), 50 ng ml-l anti-TGF-P1 (lanes 2 and 7), 10 lM TAM
(lanes 3 and 8), 10 ILM TAM + 50 ngml-' IgG2,, (lanes 4 and 9),
and 10 IM TAM+ 50 ngml- anti-TGF-P1 (lanes 5 and 10). The
results shown are typical of the four experiments performed.
12-24h (Table I) (Perry et al., 1995). In the present study
addition of anti-TGF-P1 antibody inhibited TAM-induced
internucleosomal DNA cleavage (Figure 6), a strong indica-
tion that induction of TGF-PJ by TAM triggers apoptosis.
Cycloheximide treatment significantly increased accumulation
of TAM-induced TGF-P1 mRNA, an increase typically seen
with death-associated mRNAs (Owens et al., 1991). TGF-P3
may trigger apoptosis by activation of signal transduction
pathways (Rotello et al., 1991), by effects on c-myc expres-
sion (Moses et al., 1990; Taetle et al., 1993), or by effects of
GI phase cyclins (Mercer, 1993).
Although MCF-7 cells are slightly more sensitive to TAM-
induced apoptosis (Perry et al., 1995), in this study we found
no significant difference between the two cells lines in the
degree or time course of TAM induction of TGF-pf. Oest-
rogen inhibits TAM-induced cytostasis and apoptosis in
MCF-7 cells but not in MDA-231 cells, suggesting that TAM
induces apoptosis via both ER-dependent and ER-indep-
endent pathways (Perry et al., 1995). However, oestrogen did
not inhibit TAM-induced TGF-PI expression in the present
study, indicating that TAM may induce TGF-,B through an
ER-independent mechanism.
TAM has previously been shown to elicit TGF-13I produc-
tion in MCF-7 cells (Knabbe et al., 1987), as well as from
fibroblasts lacking ER (Colletta et al., 1990). Low doses of
TAM (. 1 I M) induce TGF-PI expression even though there
is no significant effect on TGF-PI mRNA expression (Knabbe
et al., 1987). Similar results have been shown by Arrick et al.
(1990) in a panel of ER( +) and ER( -) cell lines, indicating
that TAM at low doses may have a direct effect on TGF-P3
translation. In the present study higher doses of TAM
(10gM) increased TGF-P3 protein and mRNA expression in
MCF-7 and MDA-231 cells. Thus, the effects of TAM on
TGF-P1 expression may be dose dependent as well as time
dependent.
The precise mechanism whereby TAM effects TGF-P1 ex-
pression is unknown. TAM has been shown to have a variety
of effects on cellular genes which are gene specific, dose
dependent, and tissue specific (Lau et al., 1991). TAM has
:::,.Tamoxifen,TGF-P2, cell cycle and apoptosis
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been shown to have effects on several immediate early res-
ponse genes such asfos andjun (Lau et al., 1991; Nephew et
al., 1993), whose products bind to the control regions of
genes containing activator protein 1 (AP-1) specific seq-
uences. TAM has also been shown to inhibit growth factor
induced AP-l-dependent transcriptional activity (Phillips et
al., 1993). AP-1 binds to phorbol ester-responsive elements
which have been identified in the potential TGF-P1 regulatory
domain (Scotto et al., 1990; Nutt et al., 1991). In the present
study TAM induction of TGF-P1 mRNA was not inhibited
by cycloheximide, suggesting that at least some of the effects
of TAM on TGF-P1 may be direct, rather than indirectly
mediated through effects on other genes.
The results of this study along with our previous work
suggest that TGF-P, may be an important mediator of TAM-
induced cell cycle kinetic changes, cytostasis and apoptosis.
The effects of TAM on TGF-1,3 expression appear to be
independent of ER status and may be due to a direct
regulatory effect on TGF-,B transcription. Whether these
results will hold true in other models in vitro or in vivo
remains to be determined. Understanding the mechanisms
whereby TAM exerts anti-tumour activity may lead to the
development of novel and potentially useful approaches for
treating cancer.
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